Revising the definition of Alzheimer's disease: a new lexicon

Bruno Dubois; Howard H. Feldman; Claudia Jacova; Jeffrey L. Cummings; Steven T. Dekosky; Pascale Barberger-Gateau; Andre Delacourte; Giovanni Frisoni; Nick C. Fox; Douglas Galasko; Serge Gauthier; Harald Hampel; Gregory A. Jicha; Kenichi Meguro; John T. O'Brien; Florence Pasquier; Philippe H. Robert; Martin Rossor; Steven Salloway; Marie Sarazin; Leonardo C. de Souza; Yaakov Stern; Pieter J. Visser; Philip Scheltens

doi:10.1016/S1474-4422(10)70223-4

Revising the definition of Alzheimer's disease: a new lexicon

Bruno Dubois^*, Howard H. Feldman, Claudia Jacova, Jeffrey L. Cummings, Steven T. Dekosky, Pascale Barberger-Gateau, Andre Delacourte, Giovanni Frisoni, Nick C. Fox, Douglas Galasko, Serge Gauthier, Harald Hampel, Gregory A. Jicha, Kenichi Meguro, John T. O'Brien, Florence Pasquier, Philippe H. Robert, Martin Rossor, Steven Salloway, Marie SarazinLeonardo C. de Souza, Yaakov Stern, Pieter J. Visser, Philip Scheltens

^*Corresponding author for this work

MHeNs School for Mental Health and Neuroscience

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Alzheimer's disease (AD) is classically defined as a dual clinicopathological entity. The recent advances in use of reliable biomarkers of AD that provide in-vivo evidence of the disease has stimulated the development of new research criteria that reconceptualise the diagnosis around both a specific pattern of cognitive changes and structural/biological evidence of Alzheimer's pathology. This new diagnostic framework has stimulated debate about the definition of AD and related conditions. The potential for drugs to intercede in the pathogenic cascade of the disease adds some urgency to this debate. This paper by the International Working Group for New Research Criteria for the Diagnosis of AD aims to advance the scientific discussion by providing broader diagnostic coverage of the AD clinical spectrum and by proposing a common lexicon as a point of reference for the clinical and research communities. The cornerstone of this lexicon is to consider AD solely as a clinical and symptomatic entity that encompasses both predementia and dementia phases.

Original language	English
Pages (from-to)	1118-1127
Journal	Lancet Neurology
Volume	9
Issue number	11
DOIs	https://doi.org/10.1016/S1474-4422(10)70223-4
Publication status	Published - Nov 2010

Access to Document

10.1016/S1474-4422(10)70223-4

Cite this

Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., Dekosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., Gauthier, S., Hampel, H., Jicha, G. A., Meguro, K., O'Brien, J. T., Pasquier, F., Robert, P. H., Rossor, M., Salloway, S., ... Scheltens, P. (2010). Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurology, 9(11), 1118-1127. https://doi.org/10.1016/S1474-4422(10)70223-4

@article{1cffb2d01c5742b9a03add5acd76449d,

title = "Revising the definition of Alzheimer's disease: a new lexicon",

abstract = "Alzheimer's disease (AD) is classically defined as a dual clinicopathological entity. The recent advances in use of reliable biomarkers of AD that provide in-vivo evidence of the disease has stimulated the development of new research criteria that reconceptualise the diagnosis around both a specific pattern of cognitive changes and structural/biological evidence of Alzheimer's pathology. This new diagnostic framework has stimulated debate about the definition of AD and related conditions. The potential for drugs to intercede in the pathogenic cascade of the disease adds some urgency to this debate. This paper by the International Working Group for New Research Criteria for the Diagnosis of AD aims to advance the scientific discussion by providing broader diagnostic coverage of the AD clinical spectrum and by proposing a common lexicon as a point of reference for the clinical and research communities. The cornerstone of this lexicon is to consider AD solely as a clinical and symptomatic entity that encompasses both predementia and dementia phases.",

author = "Bruno Dubois and Feldman, {Howard H.} and Claudia Jacova and Cummings, {Jeffrey L.} and Dekosky, {Steven T.} and Pascale Barberger-Gateau and Andre Delacourte and Giovanni Frisoni and Fox, {Nick C.} and Douglas Galasko and Serge Gauthier and Harald Hampel and Jicha, {Gregory A.} and Kenichi Meguro and O'Brien, {John T.} and Florence Pasquier and Robert, {Philippe H.} and Martin Rossor and Steven Salloway and Marie Sarazin and {de Souza}, {Leonardo C.} and Yaakov Stern and Visser, {Pieter J.} and Philip Scheltens",

year = "2010",

month = nov,

doi = "10.1016/S1474-4422(10)70223-4",

language = "English",

volume = "9",

pages = "1118--1127",

journal = "Lancet Neurology",

issn = "1474-4422",

publisher = "Elsevier Science",

number = "11",

}

Dubois, B, Feldman, HH, Jacova, C, Cummings, JL, Dekosky, ST, Barberger-Gateau, P, Delacourte, A, Frisoni, G, Fox, NC, Galasko, D, Gauthier, S, Hampel, H, Jicha, GA, Meguro, K, O'Brien, JT, Pasquier, F, Robert, PH, Rossor, M, Salloway, S, Sarazin, M, de Souza, LC, Stern, Y, Visser, PJ & Scheltens, P 2010, 'Revising the definition of Alzheimer's disease: a new lexicon', Lancet Neurology, vol. 9, no. 11, pp. 1118-1127. https://doi.org/10.1016/S1474-4422(10)70223-4

TY - JOUR

T1 - Revising the definition of Alzheimer's disease: a new lexicon

AU - Dubois, Bruno

AU - Feldman, Howard H.

AU - Jacova, Claudia

AU - Cummings, Jeffrey L.

AU - Dekosky, Steven T.

AU - Barberger-Gateau, Pascale

AU - Delacourte, Andre

AU - Frisoni, Giovanni

AU - Fox, Nick C.

AU - Galasko, Douglas

AU - Gauthier, Serge

AU - Hampel, Harald

AU - Jicha, Gregory A.

AU - Meguro, Kenichi

AU - O'Brien, John T.

AU - Pasquier, Florence

AU - Robert, Philippe H.

AU - Rossor, Martin

AU - Salloway, Steven

AU - Sarazin, Marie

AU - de Souza, Leonardo C.

AU - Stern, Yaakov

AU - Visser, Pieter J.

AU - Scheltens, Philip

PY - 2010/11

Y1 - 2010/11

N2 - Alzheimer's disease (AD) is classically defined as a dual clinicopathological entity. The recent advances in use of reliable biomarkers of AD that provide in-vivo evidence of the disease has stimulated the development of new research criteria that reconceptualise the diagnosis around both a specific pattern of cognitive changes and structural/biological evidence of Alzheimer's pathology. This new diagnostic framework has stimulated debate about the definition of AD and related conditions. The potential for drugs to intercede in the pathogenic cascade of the disease adds some urgency to this debate. This paper by the International Working Group for New Research Criteria for the Diagnosis of AD aims to advance the scientific discussion by providing broader diagnostic coverage of the AD clinical spectrum and by proposing a common lexicon as a point of reference for the clinical and research communities. The cornerstone of this lexicon is to consider AD solely as a clinical and symptomatic entity that encompasses both predementia and dementia phases.

AB - Alzheimer's disease (AD) is classically defined as a dual clinicopathological entity. The recent advances in use of reliable biomarkers of AD that provide in-vivo evidence of the disease has stimulated the development of new research criteria that reconceptualise the diagnosis around both a specific pattern of cognitive changes and structural/biological evidence of Alzheimer's pathology. This new diagnostic framework has stimulated debate about the definition of AD and related conditions. The potential for drugs to intercede in the pathogenic cascade of the disease adds some urgency to this debate. This paper by the International Working Group for New Research Criteria for the Diagnosis of AD aims to advance the scientific discussion by providing broader diagnostic coverage of the AD clinical spectrum and by proposing a common lexicon as a point of reference for the clinical and research communities. The cornerstone of this lexicon is to consider AD solely as a clinical and symptomatic entity that encompasses both predementia and dementia phases.

U2 - 10.1016/S1474-4422(10)70223-4

DO - 10.1016/S1474-4422(10)70223-4

M3 - Article

SN - 1474-4422

VL - 9

SP - 1118

EP - 1127

JO - Lancet Neurology

JF - Lancet Neurology

IS - 11

ER -